Latest News - Glaucoma

Monday, January 09, 2017 | Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland

Aerie Pharmaceuticals announced that it has entered into a lease agreement with the Industrial Development Agency (IDA) of Ireland for a new manufacturing plant in Athlone, Ireland. This will be Aerie…

Read the full story

Monday, December 12, 2016 | Glaucoma, Medical Studies

Three-year Study Shows Significant Advantages of CLASS (CO2 Laser Assisted Sclerectomy Surgery) for Patients with Glaucoma

IOPtima announced the publication of 3-year follow up data from a multicenter study of patients undergoing CLASS (CO2 Laser Assisted Sclerectomy Surgery) with IOPtima’s IOPtiMate CO2 laser syste…

Read the full story

Monday, December 12, 2016 | Glaucoma, Medical Studies, Glaukos Corporation

Study Published in Journal of Glaucoma Evaluates a Single Glaukos iStent Trabecular Micro-Bypass Stent as a Standalone Procedure

Glaukos Corporation announced that a study published recently in the Journal of Glaucoma showed that a single iStent Trabecular Micro-Bypass Stent significantly reduced IOP when implanted as a standal…

Read the full story

Monday, December 12, 2016 | Glaucoma, Medical Studies

Antihypertensive Medications May Have Protective Effect Against Developing Glaucoma

Antihypertensive medications may have a preventive effect on developing glaucoma in people 40 years old or older, according to results of a study of the Danish population[1]. "Cardiologists shoul…

Read the full story

Thursday, December 01, 2016 | Glaucoma

Zika and Glaucoma Linked for First Time in New Study

A team of researchers in Brazil and at the Yale School of Public Health has published the first report demonstrating that the Zika virus can cause glaucoma in infants who were exposed to the virus dur…

Read the full story

Wednesday, November 23, 2016 | Glaucoma

Virtual Glaucoma Clinics Appear Safe, Study Finds

Remote assessment of glaucoma patients appears to be a safe and practical means of monitoring this chronic disease, according to U.K. researchers. "Although meeting our patients face to face has …

Read the full story

Tuesday, November 08, 2016 | Clinical Trials, Glaucoma, Medical Studies, Glaukos Corporation, MIGS

New International Study Highlights IOP-Lowering Performance of Glaukos iStent inject Trabecular Micro-Bypass in Standalone Procedure

Glaukos announced that in a study published in Advances in Therapy, 100% of 57 phakic eyes with open angle glaucoma achieved a ≥ 20% reduction in unmedicated IOP 1 year after implantation of the iS…

Read the full story

Monday, October 31, 2016 | Clinical Trials, Glaucoma, Glaukos Corporation, MIGS

Report: iStent Trabecular Micro-Bypass Stent Reduced IOP and Medication Use in Predominately Hispanic Glaucoma Patient Population

Glaukos Corporation announced that a study of 134 predominantly Hispanic eyes with open-angle glaucoma (OAG), published in Clinical Ophthalmology, showed mean IOP of 12.9 mm Hg and a 61% decrease in m…

Read the full story

Thursday, October 27, 2016 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive Topline Efficacy Results of Rocket 4 Phase 3 Trial of Rhopressa

Aerie Pharmaceuticals reported the successful 90-day topline efficacy results of its Rocket 4 phase 3 clinical trial of product candidate Rhopressa, a novel once-daily eye drop being tested for its ab…

Read the full story

Tuesday, October 18, 2016 | Glaucoma, Medical Studies

Promise of Gene Therapy for Glaucoma Shines Bright in Award-Winning Image

Whether you see the gossamer wings of a butterfly or the delicate opened petals of a flower, there is beauty in the eye of the beholder - a mouse retina described and visually captured by scientists a…

Read the full story

Tuesday, October 18, 2016 | Clinical Trials, Glaucoma, Envisia Therapeutics

Envisia Therapeutics Releases ENV515 (Travoprost XR) Phase 2 Data Showing 9-Month Duration Of Action After A Single Dose In Patients With Glaucoma

Envisia Therapeutics released an interim analysis of its ENV515 (travoprost XR) phase 2 trial in glaucoma patients showing clinically meaningful reduction in IOP for the entire 9-month evaluation peri…

Read the full story

Wednesday, October 05, 2016 | Clinical Trials, Glaucoma, Ocular Therapeutix

Ocular Therapeutix Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP for the Treatment of Glaucoma and Ocular Hypertension

Ocular Therapeutix announced the enrollment of the first patient in the first of two planned phase 3 clinical trials with OTX-TP (sustained release travoprost) for the treatment of glaucoma and ocular…

Read the full story

Tuesday, September 27, 2016 | Glaucoma, Medical Studies, Glaukos Corporation, MIGS

New Study Underscores Ability of iStent to Achieve Sustained Reductions in IOP and Medication Use

A study published in Clinical Ophthalmology showed that a consistent cohort of 107 open-angle glaucoma (OAG) eyes receiving the iStent Trabecular Micro-Bypass Stent in combination with cataract surger…

Read the full story

Friday, September 23, 2016 | Glaucoma, Medical Studies, Glaukos Corporation, MIGS

International Study Shows Favorable 3-Year Results of 2 Glaukos iStent Trabecular Micro-Bypass Stents as Initial Treatment for Naïve Glaucoma

Glaukos announced that an international study published in Ophthalmology and Therapy showed that newly diagnosed primary open-angle glaucoma patients achieved a 43% reduction in mean IOP to 14.6 mm Hg…

Read the full story

Friday, September 09, 2016 | CE Mark Approval, Glaucoma

Sight Sciences Announces CE Mark Approval of the VISCO 360 Viscosurgical System for the Surgical Treatment of Glaucoma

Sight Sciences announced that the initial European commercial cases with the CE mark approved VISCO 360 Viscosurgical System will be presented September 12 during the European Society of Cataract and …

Read the full story
Load More